SAN DIEGO, CA — CV Sciences, Inc. (OTCQB:CVSI), a leading company in the consumer wellness sector, has announced that it will release its financial results for the fiscal year and fourth quarter ending December 31, 2025. The announcement is scheduled for March 26, 2026, following the close of the stock market.
On the same day, the company will conduct a conference call with investors at 1:30 PM Pacific Time (4:30 PM Eastern Time). Interested parties are encouraged to join the call by dialing in 15 minutes early due to anticipated high participation. The call will also feature a webcast that can be accessed via the Investor Relations section of the company’s website. An archived version will be available for a month post-call.
CV Sciences is known for its extensive range of hemp extracts and other natural wellness products. Its +PlusCBD™ brand is highlighted as a leading seller in the natural products marketplace, showcasing the company's commitment to quality and innovation. Additionally, CV Sciences is focused on developing non-cannabinoid supplements and plant-based food products, aiming to meet diverse consumer needs.
As a prominent player in the hemp extract industry, CV Sciences has gained recognition for its science-backed product claims and efforts to secure Generally Recognized as Safe (GRAS) status for its +PlusCBD™ line. Its offerings not only cater to B2B and B2C markets in the U.S. but also extend to selected markets in Europe, underlining its growth trajectory.
Investors are poised to gain insights into the company’s recent performance and strategic initiatives during the upcoming conference call. The results are expected to reflect CV Sciences' ongoing efforts to carve a significant niche in the natural wellness sector.
CV Sciences is set to announce its financial results for the year ending December 31, 2025, after the market closes on March 26, 2026. This timing allows for an immediate market response to the results, which could be indicative of the company's ongoing performance.
Investors can participate in the conference call scheduled for March 26, 2026, at 1:30 PM Pacific Time. Dialing in 15 minutes early is recommended due to expected high demand, ensuring access to valuable insights directly from company executives.
Investors can anticipate a detailed overview of CV Sciences’ performance in 2025, alongside insights into market trends and strategic direction. Given the company’s established position in the hemp extract sector, results may reflect a positive trajectory.
CV Sciences offers a diverse range of products, including their well-known +PlusCBD™ brand, which leads in the hemp extract market. Their continued investment in scientific research adds credibility, potentially driving future sales growth.
CV Sciences has invested significantly in research to secure self-affirmed Generally Recognized as Safe (GRAS) status for its +PlusCBD™ brand. This proactive approach not only reinforces product integrity but also aligns with consumer safety expectations.
CV Sciences has a multifaceted presence, with products sold through various channels in both the B2B and B2C markets. Their reach includes select retail locations in the U.S. and distribution in the EU, highlighting their strategic growth potential.
The Cultured Foods brand expands CV Sciences’ portfolio by catering to the growing demand for vegan and gluten-free options. This diversification is crucial in tapping into evolving consumer preferences, potentially enhancing market share.
Investors can access further information through CV Sciences' website and official channels. Keeping an eye on their Investor Relations section can provide valuable updates and insights into company developments.